tbuckley/cabot-search huggingface dataset:
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Authors: Alice Tison, Gilles Quéré, Laurent Misery, Elisa Funck‐Brentano, François‐Xavier Danlos, Emilie Routier, Caroline Robert, Yohann Loriot, Olivier Lambotte, Bertille Bonniaud, Camille Scalbert, Sarah Maanaoui, Thierry Lesimple, Stéphanie Martinez, Marie Marcq, Christos Chouaid, Catherine Dubos, Florence Brunet‐Possenti, Chloé Stavris, Laurent Chiche, Nathalie Beneton, Sandrine Mansard, Florian Guisier, Hélène Doubre, François Skowron, François Aubin, Ouidad Zehou, Christophe Roge, Mickaël Lambert, Anne Pham‐Ledard, Marie Beylot‐Barry, Rémi Veillon, Nora Kramkimel, Damien Giacchero, Julie De Quatrebarbes, Catherine Michel, Jean‐Bernard Auliac, Gilles Gonzales, Chantal Decroisette, Gwenaelle Le Garff, Ioana Carpiuc, Hervé Vallerand, Emmanuel Nowak, Divi Cornec, Marie Kostine
Journal: Arthritis & Rheumatology (2019)

Immune checkpoint inhibitors (ICIs) for cancer therapy frequently induce immune-related adverse effects (IRAEs). Therefore, most patients with preexisting autoimmune diseases have been excluded from clinical trials of ICIs. This study was undertaken to evaluate the safety and efficacy of ICIs in patients with preexisting autoimmune disease and cancer.A retrospective cohort study was conducted from January 2017 to January 2018 via 3 French national networks of experts in oncology and autoimmunity. Adults with preexisting autoimmune disease who were receiving ICIs were assessed for the occurrence of flare of preexisting autoimmune disease, other IRAEs, and cancer response.The study included 112 patients who were followed up for a median of 8 months. The most frequent preexisting autoimmune diseases were psoriasis (n = 31), rheumatoid arthritis (n = 20), and inflammatory bowel disease (n = 14). Twenty-four patients (22%) were receiving immunosuppressive therapy at ICI initiation. Autoimmune disease flare and/or other IRAE(s) occurred in 79 patients (71%), including flare of preexisting autoimmune disease in 53 patients (47%) and/or other IRAE(s) in 47 patients (42%), with a need for immunosuppressive therapy in 48 patients (43%) and permanent discontinuation of ICI in 24 patients (21%). The median progression-free survival was shorter in patients receiving immunosuppressive therapy at ICI initiation (3.8 months versus 12 months; P = 0.006), confirmed by multivariable analysis. The median progression-free survival was shorter in patients who experienced a flare of preexisting autoimmune disease or other IRAE, with a trend toward better survival in the subgroup without immunosuppressant use or ICI discontinuation.Our findings indicate that flares or IRAEs occur frequently but are mostly manageable without ICI discontinuation in patients with a preexisting autoimmune disease. Immunosuppressive therapy at baseline is associated with poorer outcomes.
Myeloma and the Microenvironment: Macrophages Are a Protector of Myeloma Cells Apoptosis Induced by Chemotherapy Drugs.
Authors: Jing Yang, Yuhuan Zheng, Zhen Cai, Jianfei Qian, Sungyoul Hong, Haiyan Li, Jairo A. Matthews, Michael Wang, Qing Yi
Journal: Blood (2009)
Biphenotypic Blast Phase (B-BP) of Chronic Myeloid Leukemia (CML): A Single Institution Experience
Authors: Hady Ghanem, Hagop M. Kantarjian, Elias Jabbour, Lakshmikanth Katragadda, Jorge E. Cortes, Naveen Pemmaraju, Alfonso Quintás-Cardama
Journal: Blood (2012)
Racial and Ethnic Differences in 30-Day Hospital Readmissions Among US Adults With Diabetes
Authors: Rene Rodriguez-Gutierrez, Jeph Herrin, Kasia J. Lipska, Victor M. Montori, Nilay D. Shah, Rozalina G. McCoy
Journal: JAMA Network Open (2019)

Differences in readmission rates among racial and ethnic minorities have been reported, but data among people with diabetes are lacking despite the high burden of diabetes and its complications in these populations.To examine racial/ethnic differences in all-cause readmission among US adults with diabetes and categorize patient- and system-level factors associated with these differences.This retrospective cohort study includes 272 758 adult patients with diabetes, discharged alive from the hospital between January 1, 2009, and December 31, 2014, and stratified by race/ethnicity. An administrative claims data set of commercially insured and Medicare Advantage beneficiaries across the United States was used. Data analysis took place between October 2016 and February 2019.Unplanned all-cause readmission within 30 days of discharge and individual-, clinical-, economic-, index hospitalization-, and hospital-level risk factors for readmission.A total of 467 324 index hospitalizations among 272 758 adults with diabetes (mean [SD] age, 67.7 [12.7]; 143 498 [52.6%] women) were examined. The rates of 30-day all-cause readmission were 10.2% (33 683 of 329 264) among white individuals, 12.2% (11 014 of 89 989) among black individuals, 10.9% (4151 of 38 137) among Hispanic individuals, and 9.9% (980 of 9934) among Asian individuals (P < .001). After adjustment for all factors, only black patients had a higher risk of readmission compared with white patients (odds ratio, 1.05; 95% CI, 1.02-1.08). This increased readmission risk among black patients was sequentially attenuated, but not entirely explained, by other demographic factors, comorbidities, income, reason for index hospitalization, or place of hospitalization. Compared with white patients, both black and Hispanic patients had the highest observed-to-expected (OE) readmission rate ratio when their income was low (annual household income <$40 000 among black patients: OE ratio, 1.11; 95% CI, 1.09-1.14; among Hispanic patients: OE ratio, 1.11; 95% CI, 1.07-1.16) and when they were hospitalized in nonprofit hospitals (black patients: OE ratio, 1.10; 95% CI, 1.08-1.12; among Hispanic patients: OE ratio, 1.08; 95% CI, 1.05-1.12), academic hospitals (black patients: OE ratio, 1.16; 95% CI, 1.13-1.20; Hispanic patients: OE ratio, 1.12; 95% CI, 1.06-1.19), or large hospitals (ie, with ≥400 beds; black patients: OE ratio, 1.11; 95% CI, 1.09-1.14; Hispanic patients: OE ratio, 1.09; 95% CI, 1.04-1.14).In this study, black patients with diabetes had a significantly higher risk of readmission than members of other racial/ethnic groups. This increased risk was most pronounced among lower-income patients hospitalized in nonprofit, academic, or large hospitals. These findings reinforce the importance of identifying and addressing the many reasons for persistent racial/ethnic differences in health care quality and outcomes.
Survival Improvements Following Myeloablative Allogeneic Hematopoietic Cell Transplantation For Acute Lymphoblastic Leukemia In Adolescents and Young Adults Have Been Comparable To Younger Children: A Study From The Cibmtr
Authors: William A. Wood, Stephanie J. Lee, Ruta Brazauskas, Zhiwei Wang, Mahmoud D. Aljurf, Karen K. Ballen, David K. Buchbinder, Jason Dehn, César O Freytes, Hillard M. Lazarus, Charles F. LeMaistre, Paulette Mehta, David Szwajcer, Steven Joffe, Navneet S. Majhail
Journal: Blood (2013)
Genomic Variability in Multiple Myeloma (MM) Patients By Race: An Analysis of the Publically Available Mmrf Commpass Study Database
Authors: Aneel Paulus, Mayank Sharma, Shumail M. Paulus, Richa Menghani, Elisa M. Rodriguez, Ryan D Frank, George Cooper, David Hodge, Vivek Roy, Rafael Fonseca, Asher A. Chanan-Khan, Peter Leif Bergsagel, Sikander Ailawadhi
Journal: Blood (2016)
Microrna-155 Promotes Hematopoietic Stem and Progenitor Cell Mobilization and Proliferation
Authors: Tomer Itkin, Aya Ludin, Shiri Gur-Cohen, Carolin Ludwig, Robert Brooks, Karin Golan, Kfir Lapid, Giulia Caglio, William Kerr, Florian Kuchenbauer, Eran Hornstein, Tsvee Lapidot
Journal: Blood (2012)
Expansion of AML Blasts Induces CD14 Expression and Facilitates Leukemic DC Development for Therapeutic Application In AML
Authors: Willemijn van den Ancker, Pepijn G.J.T.B. Wijnands, Theresia M. Westers, Hetty J. Bontkes, Sandra van Wetering, Ada M. Kruisbeek, Gert J. Ossenkoppele, Tanja D. de Gruijl, Arjan A. Van de Loosdrecht
Journal: Blood (2010)
A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma
Authors: Uma Borate, Amir T. Fathi, Bijal D. Shah, Daniel J. DeAngelo, Lewis B. Silverman, Todd Michael Cooper, Tina M. Albertson, Megan M. O'Meara, Larissa Sandalic, Faith Stevison, Robert Chen
Journal: Blood (2013)
Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,
Authors: Drorit Merkel, Kalman Filanovsky, Ariel Aviv, Moshe E. Gatt, Yair Herishanu, Ariela Arad, Tamar Tadmor, Najib Dally, Aharon Ronson, Luiza Akria, Andrei Braester, Arnon Nagler, Ronit Leiba, Yishai Ofran
Journal: Blood (2011)
Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study
Authors: Ruben Niesvizky, Ian W. Flinn, Robert Rifkin, Nashat Gabrail, Veena Charu, Billy Clowney, James Essell, Yousuf Gaffar, Thomas A. Warr, Rachel Neuwirth, Deyanira Corzo, James Reeves
Journal: Blood (2011)
The Prognostic Significance of the Absolute Lymphocyte to Monocyte Count Ratio (ALC/AMC-dx) at Diagnosis in Hodgkin´s Lymphoma
Authors: Brenda Lizeth Acosta-Maldonado, Ana Ramirez-Ibarguen, Flavio A Grimaldo-Gomez, Luis Oñate-Ocaña, Silvia Rivas-Vera
Journal: Blood (2014)
Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy
Authors: Timothy P. Hughes, Yeow-Tee Goh, Oliver G. Ottmann, Hironobu Minami, Delphine Rea, Fabian Lang, Michael J. Mauro, Daniel J. DeAngelo, Moshe Talpaz, Andreas Hochhaus, Massimo Breccia, Jorge E. Cortes, Michael C. Heinrich, Jeroen Janssen, Juan-Luis Steegmann, François-Xavier Mahon, Raina Duan, Varsha Iyer, David Hynds, Gary J. Vanasse, Dong-Wook Kim
Journal: Blood (2016)
Reduced-Intensity Cord Blood Transplantation (RICBT) Is a Feasible Approach for Advanced Adult T-Cell Leukemia (ATL).
Authors: Atsushi Wake, Daisuke Kato, Shinsuke Takagi, Tomomi Kawano, Eiji Kusumi, Tomoko Matsumura, Hiroto Narimatsu, Koichiro Yuji, Kazuhiro Masuoka, Naoyuki Uchida, Shigesaburo Miyakoshi, Shuichi Taniguchi
Journal: Blood (2005)
Favorable Outcomes of Autologous Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Remission: On Behalf of the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)
Authors: Harumi Kato, Takakazu Kawase, Shinichi Kako, Shuichi Mizuta, Kazuteru Ohashi, Mineo Kurokawa, Koji Iwato, Takehiko Mori, Ritsuro Suzuki, Hisashi Sakamaki, Yasuo Morishima, Junji Tanaka
Journal: Blood (2012)
Long-Term Use of Low-Molecular-Weight Heparin (LMWH) for Cancer-Associated Venous Thromboembolism (VTE): Adherence to Recommendations in Clinical Practice Based on Tropique, a Prospective Non-Interventional Observational Study
Authors: Dominique Farge, Norbert Claude Gorin, Philippe Debourdeau, Anne Lamblin, Francis Cajfinger
Journal: Blood (2014)
A Novel Homozygous CTC1 Germline Mutation Associated with Bone Marrow Failure
Authors: Ulla Wartiovaara-Kautto, Elina A. M. Hirvonen, Kaisa Kettunen, Anna Nordberg, Janna Saarela, Kimmo Porkka, Tero Kivelä, Tarja Linnankivi, Outi Kilpivaara
Journal: Blood (2016)
Prognostic Factors of CLL Patients Undergoing Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation in the Immunochemotherapy Era
Authors: Oscar B. Lahoud, Patrick Hilden, Molly A. Maloy, Parastoo B. Dahi, Hugo Castro-Malaspina, Miguel-Angel Perales, Sergio A. Giralt, Craig S. Sauter
Journal: Blood (2016)
Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131
Authors: Karen R. Rabin, Johann Hitzler, Vilmarie Rodriguez, Reuven Schore, Anne Angiolillo, Michael J. Burke, Wanda Salzer, Kelly Maloney, Xiaomin Lu, Meenakshi Devidas, Mignon L. Loh, Elizabeth Raetz, Stephen P Hunger
Journal: Blood (2015)
A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Andre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, Javier Munoz, David S. Morgan, Nam H. Dang, Mark Knapp, Maria Delioukina, Edwin C. Kingsley, Anh Tran, Jerry Ping, Darrin M. Beaupre, Jutta K. Neuenburg, Jia Ruan
Journal: Blood (2016)
Haploidentical Hematopoietic Stem Cell Transplantation with Treosulfan-Based Conditioning Regimen for Acute Leukemia Relapsing after Initial Allogeneic Transplantation
Authors: Jacopo Peccatori, Lara Crucitti, Raffaella Greco, Maria Teresa Lupo Stanghellini, Luca Vago, Nicoletta Cieri, Corrado Zuanelli Brambilla, Fabio Giglio, Mara Morelli, Andrea Assanelli, Magda Marcatti, Matteo G Carrabba, Chiara Bonini, Massimo Bernardi, Fabio Ciceri
Journal: Blood (2014)
Impact of Rituximab and Methotrexate on the Survival of the Patients with Sinonasal Tract Diffuse Large B-Cell Lymphoma
Authors: Pauli Vähämurto, Susanna Mannisto, Marjukka Pollari, Marja-Liisa Karjalainen-Lindsberg, Antti A. Mäkitie, Sirpa Leppä
Journal: Blood (2016)
Prediction of toxicity in R/R DLBCL treated with Axicabtagene Clioleucel (19-28z CAR T)
Authors: Hiroshi Kotani, Rawan Faramand, Sae Bom Lee, Bin Yu, Dylan Morrissey, Frederick L. Locke, Michael D. Jain, Julio C. Chavez, Xuefeng Wang, Asmita Mishra, Christina A. Bachmeier, Renier J. Brentjens, Sarah Yoo, Jae H. Park, Marco L. Davila
Journal: Annals of Oncology (2019)
Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group,
Authors: Trudy Buitenkamp, Shai Izraeli, Martin Zimmermann, Erik Forestier, Nyla A. Heerema, Marry M. van den Heuvel, Rob Pieters, Válerie de Haas, Lewis B. Silverman, Kjeld Schmiegelow, Der-Cherng Liang, Keizo Horibe, Maurizio Arico, Giovanni Cazzaniga, Giuseppe Basso, Karen R. Rabin, Martin Schrappe, Gunnar Cario, Georg Mann, Veerle Mondelaers, Tim Lammens, Hélène Cavé, Batia Stark, Anthony V. Moorman, Ajay J Vora, Stephen Hunger, Ching-Hon Pui, Charles G Mullighan, Atsushi Manabe, Gabriele Escherich, Jerzy Kowalczyk, James A. Whitlock, Christian M. Zwaan
Journal: Blood (2011)
Influence Of GST Gene Polymorphisms On Busulfan Pharmacokinetics and Outcome Of Hematopoietic Stem Cell Transplantation In Thalassemia Pediatric Patients
Authors: Marc Ansari, Aziz Resgui, Patricia Huezo-Diaz, Sarah Marktel, Michel Duval, Henrique Bittencourt, Barbara Cappelli, Maja Krajinovic
Journal: Blood (2013)
The B-Cell Receptor of Primary Cutaneous Follicle Center Lymphoma: Implications for Pathogenesis
Authors: Marvyn T. Koning, Sander A.J. van der Zeeuw, Willem H. Zoutman, Maarten H. Vermeer, Rein Willemze, Hendrik Veelken, Cornelis P. Tensen
Journal: Blood (2016)
Platelet Physiology and Abnormalities of Platelet Function
Authors: Harvey J. Weiss
Journal: New England Journal of Medicine (1975)

Clinical Disorders of Hemostasis Associated with Abnormal Platelet FunctionThe finding of a prolonged bleeding time in a patient whose platelet count is normal suggests some abnormality of platelet function. This situation may be owing either to an inherent platelet defect (the usual case) or to the deficiency of a plasma factor necessary for some aspect of platelet function. Tests of platelet aggregation, using the aggregometer, are now widely used to investigate patients suspected of having platelet disorders. Another test is to filter venous blood through a column of glass beads and determine the percentage of . . .
Inhibition of Impdh As an Effective Treatment for MLL-Fusion Leukemia
Authors: Susumu Goyama, Shiori Shikata, Yasutaka Hayashi, Yuto Izawa, Janet Schibler, Hiroyuki Iwamura, Motoki Saito, Satoshi Kofuji, Kazutaka Sumita, Atsuo T Sasaki, James C. Mulloy, Toshio Kitamura
Journal: Blood (2016)
Characterization of Immunosuppressive Cells Using MultiOmyx in Hematological Malignancies
Authors: Qingyan Au, Arezoo Hanafi, Erinn Parnell, Judy Kuo, Eric Leones, Flora Sahafi, Raghavkrishna Padmanabhan, Nicholas Hoe, Josette William
Journal: Annals of Oncology (2019)
MM-derived exosomes can promote apoptosis and inhibit proliferation of HD-CD4+T, inhibit apoptosis and promote proliferation but inhibit perforin secretion of HD-CD8+T, inhibit apoptosis and promote proliferation HD-Treg, and promotes IL-10 secretion
Authors: Rong Fu, Qing Shao, Liu Zhaoyun, Hui Liu, Jin Chen, Zonghong Shao
Journal: Blood (2018)
Alternative Splicing Due to an Intronic SNP Defines a Novel HLA-B44-Restricted-Hematopoiesis-Restricted Minor Histocompatibility Antigen.
Authors: Takakazu Kawase, Yoshiki Akatsuka, Hiroki Torikai, Satoko Morishima, Yoshihisa Kodera, Yasuo Morishima, Kiyotaka Kuzushima, Toshitada Takahashi
Journal: Blood (2006)
Analysis of Wnt and Hedgehog Pathways Regulating Protein Kinases CK1 and CK2 in Acute Myeloid Leukemia Cells and Stem Cells: Correlation with the Expression of Wnt and Hedgehog Targets and Biological and Clinical Features.
Authors: Alessandra Brancalion, Laura Quotti Tubi, Sabrina Manni, Anna Cabrelle, Fortunato Zaffino, Carmela Gurrieri, Gianpietro Semenzato, Francesco Piazza
Journal: Blood (2012)
MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL)
Authors: Stefano Molica, Diana Giannarelli, Massimo Gentile, Giovanna Cutrona, Antonino Neri, Massimo Federico, Manlio Ferrarini, Fortunato Morabito
Journal: Blood (2013)
Molecular Immunoprofiling the T Cell Repertoire after Rituximab Administration Reveals Frequent Oligoclonality Albeit with Different Patterns Depending on the Clinical Context
Authors: Apostolia Papalexandri, Michail Iskas, Evangelia Stalika, Maria Karypidou, Barbara Tachynopoulou, Konstantina Kotta, Panagiota Zerva, George Kanellis, Ioanna Sakellari, Niki Stavroyianni, Achilles Anagnostopoulos, Theodora Papadaki, Kostas Stamatopoulos
Journal: Blood (2016)
An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia
Authors: Denis M Schewe, Ameera Alsadeq, Gunnar Cario, Simon Vieth, Thomas Valerius, Martin Schrappe, Martin Gramatzki, Matthias Peipp, Christian Kellner
Journal: Blood (2016)
Quantitative Imaging of Femoral Bone Marrow Microenvironments Reveals a Heterogenous Distribution of Hematopoietic Stem and Progenitor Cells.
Authors: Cesar Nombela-Arrieta, Brendan Harley, Gregory Pivarnik, John E Mahoney, Elena Levantini, Alexei Protopopov, Daniel G. Tenen, Leslie E. Silberstein
Journal: Blood (2009)
Invasive pulmonary aspergillosis in critically ill patients with hematological malignancies
Authors: Emmanuel Pardo, Virginie Lemiale, Djamel Mokart, Annabelle Stoclin, Anne-Sophie Moreau, Lionel Kerhuel, Laure Calvet, Sandrine Valade, Audrey De Jong, Michael Darmon, Elie Azoulay
Journal: Intensive Care Medicine (2019)
Deferiprone Versus Deferoxamine in Thalassemia Intermedia: Results from 5-Year Long-Term Italian Multi-Center Randomized Clinical Trial
Authors: Angela Vitrano, Giuseppina Calvaruso, Rosario Di Maggio, Massimiliano Sacco, Alessandra Quota, Marcello Capra, Aldo Filosa, Domenico Giuseppe D'Ascola, Carmelo Fidone, Antonella Carollo, Lorella Pitrolo, Calogera Gerardi, Grazia Colletti, Gaetano Roccamo, Maria Antonietta Romeo, Paolo Cianciulli, Maria-Eliana Lai, Luciana Concetta Rigoli, Gianluca Forni, Aurelio Maggio
Journal: Blood (2014)
MGCD0103, an oral isotype-selective HDAC inhibitor, significantly enhances the anti-tumor efficacy of Taxane via the unique modulation of angiogenesis gene expressions
Authors: Hidenori Fujita, Koji Murakami, Daisuke Nameki, Yositaka Ohsugi, Yasundo Yamasaki, Kazuharu Noguchi
Journal: Cancer Research (2008)

2446  Background:  MGCD0103 is a novel orally available and isotype-selective HDAC inhibitor whose clinical activity has been shown in multiple phase II trials in patients with relapsed or refractory Hodgkin lymphoma, high-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Here we explored the combination effects of MGCD0103 with taxanes on anti-tumor activity in several solid tumor xenograft models in mice in vivo and investigated the putative mechanism of their interaction.  Method:  MGCD0103 was orally administrated to the athymic nude mice implanted with human tumors using an intermittent dosing regimen (3 times a week) for 2 or 6 weeks. Taxol or Taxotere was administered as a bolus intravenous infusion. Tumor volume was calculated during the treatment and tumor weight at final date was measured for final evaluation. In addition, we measured the expression of angiogenesis related factors in the tumor tissue from the mice administrated with MGCD0103. The contribution of thrombospondin-1 (TSP-1) induced by MGCD0103 to the growth suppression of endothelial cells (ECs) by Taxol was investigated.  Result:  In xenograft models of human prostate, non-small cell lung (NSCLC), and gastric tumor in mice, MGCD0103 was observed to be as active as taxanes in inhibiting tumor growth in vivo. The combination of Taxol (or Taxotere) with MGCD0103 showed better anti-tumor effect in comparison to each treatment alone. Moreover, tumor regression was observed after combination of a taxane with MGCD0103 in the NCI-H460 human NSCLC xenograft model, even though treatment was initiated when the tumor was at an advanced stage. In addition, we observed the induced expression of an anti-angiogenesis factor, thrombospondin 1 (TSP-1), and reduced expression of two angiogenesis factors, VEGF and bFGF, in tumor tissues from mice treated with MGCD0103. Consistent with the effect of MGCD0103 on the expression of anti-angiogenesis/angiogenesis factors in vivo, addition of TSP-1 potentiated the cytotoxic effect of taxanes on ECs in vitro.  Conclusion:  MGCD0103 in combination with Taxol or Taxotere showed potent anti-tumor activity in vivo in preclinical models. Our results provide a rationale for on-going clinical trials of MGCD0103 in combination with Taxotere in patients with solid tumors.